13 injections are included!

Text | MRCLUB

Today, the Jiangsu Provincial Medical Insurance Bureau issued a notice to launch the second round of centralized drug procurement in Jiangsu Province.

The announcement stated that all public and military medical institutions in Jiangsu Province participated in the procurement alliance in the second round of mass procurement

Jiangsu Province adopts group declaration for the current round of procurement, and the details are as follows:

Group A: Over-protection patent drugs, reference preparations, produced in China and obtained US FDA, EU (Germany and France only) CGMP, UK MHRA, Japan JGMP certification and exported to the US, France, Germany, UK, and Japan mainstream Drugs on the market, as well as generic drugs that have passed (including deemed passed) quality and efficacy consistency evaluation after the announcement of this announcement

Group B: other imported and domestic drugs except A group

According to the market structure of the declared drugs, the Group B companies will be further subdivided:

When the total number of companies in the same group in Group B reaches 4 or more (excluding those companies whose purchase volume of a single company reaches 50% or more of the total purchase volume of the same generic name variety, the same below), and the purchase volume of this group reaches the total purchase volume of the common name variety When the volume is 10% and above, the companies in the group further refine the bidding groupings.

The material declaration time is from 9:00 on July 8, 2021 to 12:00 on July 11, 2021.

▌ Winning rules and winning price

According to the announcement of the Jiangsu Medical Insurance Bureau, considering the attributes of drugs, the characteristics of clinical use in Jiangsu Province and the guarantee of supply, and according to the characteristics of different groups and market structure, the selected companies shall be determined by negotiation or bidding respectively: the total number of companies in Group A and Group B is different.

1.

Two rounds of negotiations are set up, with reference to the lowest global price of the negotiated drug, the price of neighboring countries and regions, the price selected for purchases from other provinces, and the price and drop rate of the selected company in the bidding of the same generic name, respectively, to set the expected prices for the two rounds of negotiations

In the first round of negotiations, the company is selected when the quoted price is not higher than the expected price in the first round, and the proportion of the quantity is 60% (50% for antibiotics)

In the second round of negotiations, the company is selected when the quoted price is not higher than the expected price in the second round, but without the quantity.

2.

The bidding companies are divided into groups (subdivided into B1 and B2 bidding groups, according to B1 and B2 bidding groups) to bid and determine the selected companies

If the number of companies in the B1 bidding group is 2 and the purchase volume is large (the purchase volume of the group is 50% or more of the total purchase volume of the same generic name), the unselected companies in the group can make the second round of quotation, and must meet at the same time When the price is lower than the price of the selected companies in the same group, and the decrease is greater than the decrease of the selected companies in the same group and the average decrease of the selected companies in the B2 bidding group of the same product, one more selected place can be selected

3.

The final quotation of the selected product or the negotiated price shall be the selected price of the product

For companies that do not accept price corrections, the qualifications to be selected will be cancelled, and those who have never been selected will be inquired in order of quotation from low to high according to the rules
.

▌ Arrangement of purchase amount allocation

1.
The agreed purchase volume of the selected drugs shall be allocated to each selected company according to the following rules:

(1) Basic purchase volume
.
The selected products receive 60% of the agreed purchase volume calculation base (50% for antibiotics, the same below), but the basic purchase volume of the selected products is determined according to the winning rules
.

(2) Adjust the purchase volume
.
60% of the agreed purchase amount vacated by the unselected products will be allocated by the relevant medical institutions among all the selected products in the same group (group B here is not subdivided), and priority will be given to the selected products in the same group with high quality and low price
.

2.
If a category A group does not produce a selection result, the relevant medical institution that has purchased the group of drugs in the previous year will calculate 60% of the agreed purchase volume of the group of drugs and include it in the medical institution’s selection of products in the same category in group B.
Adjust the purchase volume
.

3.
If the agreed procurement ratio of a product selected in a negotiation is less than 60%, the relevant medical institution that has purchased the product in the previous year will calculate the difference between the agreed procurement volume actually obtained for the selected product and the agreed procurement volume by 60% of the base Half of the amount is included in the purchase of the same type of group B adjustments by the medical institution
.